Ospedale San Raffaele S.r.L.
|Ospedale San Raffaele S.r.L. Patent applications|
|Patent application number||Title||Published|
|20140086889||METHOD FOR EXPANDING CD4+CD25+T REGULATOR CELLS - A method for generating/expanding in vitro a CD4||03-27-2014|
|20130295100||MARKERS FOR ACUTE KIDNEY INJURY AND USES THEREOF - The present invention relates to a method for predicting the risk of developing acute kidney injury in a subject from which a biological sample is obtained comprising: detecting the presence of at least one genomic single nucleotide polymorphism (SNP) selected from the group of: ADD1 rs4961 Trp [allelic genotype GT or TT], ADD2 rs4984 [allelic genotype CT or TT], HS-D3B1 rs2236780 [allelic genotype GG], LSS rs914247 [allelic genotype AA], MDR1 rs1045642 [allelic genotype TC or CC], SLC8A1 rs1 1893826 [allelic genotype AA], TRPC6 rs7925662 [allelic genotype CC] from said biological sample, wherein the presence of said allelic genotype is predictive of the risk of developing acute kidney injury.||11-07-2013|
|20130289119||FORMULATION COMPRISING ARGININE, USE AND PREPARATION THEREOF - The present invention relates to an edible formulation comprising the following ingredients (% on mix) 19 to 30 weight % of a dietary supplement comprising at least 50% of L-arginine, 20 to 35 weight % of cereal flakes, 14 to 25 weight % of puffed brown or white rice, 12 to 24 weight % of nuts, 9 to 18 weight % of orange rind (or dried fruit such as cranberries, blueberries, raspberry, blackberry) and 2 to 10 weight % of water and/or fruit juice, its use and process of preparation.||10-31-2013|
|20130143204||DETERMINATION OF IN VIVO DNA DOUBLE-STRAND BREAK LOCALIZATION AND APPLICATION THEREOF - The present invention relates to a method for determining the in vivo localization of double-strand breaks in a host cell, comprising incubating a host cell suspected to comprise DNA double-strand breaks and a linear polynucleotide comprising a known sequence, detecting the in vivo insertion sites of said polynucleotide in the genome of said host cell, and assessing the in vivo localization of double-strand breaks. Further envisaged by the present invention is a method for obtaining an endonuclease with altered in vivo specificity. Finally, the present invention is directed to a kit for determining in vivo specificity of an endonuclease.||06-06-2013|
|20130040318||INCREASE OF MYELOID MICROVESICLES IN THE CEREBROSPINAL FLUID AS BIOMARKER OF MICROGLIA/MACROPHAGE ACTIVATION IN NEUROLOGICAL DISORDERS - The present invention relates to a method for the diagnostic and/or prognostic of a neurological disease characterized by an inflammation process in a subject comprising measuring the amount of myeloid derived microvesicles in a cerebrospinal fluid sample obtained from the subject. The invention further relates to a method for predicting and/or monitoring the efficacy of a treatment for a neurological pathology or for monitoring a neurological disease progression.||02-14-2013|
Patent applications by Ospedale San Raffaele S.r.L.